Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply

doi:10.1016/S1470-2045(20)30394-6

Comment

. 2020 Aug;21(8):e371.

doi: 10.1016/S1470-2045(20)30394-6.

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply

Ghassan K Abou-Alfa¹, Shuchi S Pandya², Andrew X Zhu³

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA; Agios Pharmaceuticals, Cambridge, MA, USA.
³ Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China. Electronic address: azhu@mgh.harvard.edu.

PMID: 32758466
DOI: 10.1016/S1470-2045(20)30394-6

Comment

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply

Ghassan K Abou-Alfa et al. Lancet Oncol. 2020 Aug.

. 2020 Aug;21(8):e371.

doi: 10.1016/S1470-2045(20)30394-6.

Authors

Ghassan K Abou-Alfa¹, Shuchi S Pandya², Andrew X Zhu³

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Medicine, Weill Medical College at Cornell University, New York, NY, USA; Agios Pharmaceuticals, Cambridge, MA, USA.
³ Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA; Jiahui International Cancer Center, Jiahui Health, Shanghai, China. Electronic address: azhu@mgh.harvard.edu.

PMID: 32758466
DOI: 10.1016/S1470-2045(20)30394-6

No abstract available

PubMed Disclaimer

Comment on

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX. Abou-Alfa GK, et al. Lancet Oncol. 2020 Jun;21(6):796-807. doi: 10.1016/S1470-2045(20)30157-1. Epub 2020 May 13. Lancet Oncol. 2020. PMID: 32416072 Free PMC article. Clinical Trial.
Ivosidenib for advanced IDH1-mutant cholangiocarcinoma.
Gervaso L, Pellicori S, Fazio N. Gervaso L, et al. Lancet Oncol. 2020 Aug;21(8):e370. doi: 10.1016/S1470-2045(20)30343-0. Lancet Oncol. 2020. PMID: 32758465 No abstract available.

Cited by

Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
Martin-Serrano MA, Kepecs B, Torres-Martin M, Bramel ER, Haber PK, Merritt E, Rialdi A, Param NJ, Maeda M, Lindblad KE, Carter JK, Barcena-Varela M, Mazzaferro V, Schwartz M, Affo S, Schwabe RF, Villanueva A, Guccione E, Friedman SL, Lujambio A, Tocheva A, Llovet JM, Thung SN, Tsankov AM, Sia D. Martin-Serrano MA, et al. Gut. 2023 Apr;72(4):736-748. doi: 10.1136/gutjnl-2021-326514. Epub 2022 May 18. Gut. 2023. PMID: 35584893 Free PMC article.
Intrahepatic cholangiocarcinoma: Insights on molecular testing, targeted therapies, and future directions from a multidisciplinary panel.
Gujarathi R, Peshin S, Zhang X, Bachini M, Meeks MN, Shroff RT, Pillai A. Gujarathi R, et al. Hepatol Commun. 2025 Jun 9;9(7):e0743. doi: 10.1097/HC9.0000000000000743. eCollection 2025 Jul 1. Hepatol Commun. 2025. PMID: 40489757 Free PMC article. Review.
CircPCNXL2 promotes tumor growth and metastasis by interacting with STRAP to regulate ERK signaling in intrahepatic cholangiocarcinoma.
Liu S, Wang Y, Wang T, Shi K, Fan S, Li C, Chen R, Wang J, Jiang W, Zhang Y, Chen Y, Xu X, Yu Y, Li C, Li X. Liu S, et al. Mol Cancer. 2024 Feb 17;23(1):35. doi: 10.1186/s12943-024-01950-y. Mol Cancer. 2024. PMID: 38365721 Free PMC article.
Cholangiocarcinoma.
Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Brindley PJ, et al. Nat Rev Dis Primers. 2021 Sep 9;7(1):65. doi: 10.1038/s41572-021-00300-2. Nat Rev Dis Primers. 2021. PMID: 34504109 Free PMC article. Review.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply

Affiliations

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma - Authors' reply

Authors

Affiliations

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous